Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Entrada Therapeutics, Inc. - Common Stock (NQ:TRDA)

10.30 +0.23 (+2.28%)
Streaming Delayed Price Updated: 9:30 AM EST, Feb 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Entrada Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Entrada Therapeutics Reports Second Quarter 2024 Financial Results
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Entrada Therapeutics Announces $100 Million Registered Direct Offering
– The offering was led by a U.S.-based healthcare focused investor, two global mutual funds and Janus Henderson Investors, a global asset management firm – 
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular Dystrophy
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Recap: Entrada Therapeutics Q4 Earnings ↗
 
Via Benzinga
News headline image
Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Entrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
TRDA Stock Earnings: Entrada Therapeutics Beats EPS, Beats Revenue for Q1 2024 ↗
TRDA stock results show that Entrada Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Entrada Therapeutics Reports First Quarter 2024 Financial Results
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Insiders Buying America's Car-Mart And 2 Other Stocks ↗
Although U.S. stocks closed lower on Wednesday, there were a few notable insider trades. 
Via Benzinga
News headline image
Around $5M Bet On This Communication Services Stock? Check Out These 4 Stocks Insiders Are Buying ↗
Although U.S. stocks closed higher on Thursday, there were a few notable insider trades. 
Via Benzinga
News headline image
Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Entrada Therapeutics to Present at Upcoming Investor Conferences
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Entrada Therapeutics Promotes Nathan J. Dowden to President
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
HC Wainwright & Co. Maintains Buy Rating for Entrada Therapeutics: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Why Is Neuromuscular Disease Focused Entrada Therapeutics Shares Trading Lower Today? ↗
Entrada Therapeutics Inc (NASDAQ: TRDA) shares are trading lower after the company announced updates on ENTR-601-44 in  
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Entrada Therapeutics Reports Third Quarter 2023 Financial Results
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Entrada Therapeutics to Present at Upcoming Investor Conferences
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Entrada Therapeutics Awards Funding to Non-Profit Organizations Advancing Diversity, Equity, Inclusion and Accessibility within the Duchenne Muscular Dystrophy Community
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Entrada Therapeutics to Present at Upcoming Investor Conferences
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Entrada Therapeutics Appoints Gina Chapman to its Board of Directors
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Entrada Therapeutics Reports Second Quarter 2023 Financial Results
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Entrada Therapeutics to Present at Goldman Sachs 44th Annual Global Healthcare Conference
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Vertex Pharmaceuticals Hits Record High on Strong Q1 Earnings
Vertex Pharmaceuticals hits record high on strong earnings, FDA approval for cystic fibrosis medication for infants. Analysts recently boosted price targets. 
Via MarketBeat
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.